Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia

Journal of Pharmacological Sciences

Volumn 127, Issue 2, 2015, Pages 164-169

  Jaruratanasirikul, Sutep ^a   Wongpoowarak, Wibul ^a   Jullangkoon, Monchana ^a   Samaeng, Maseetoh ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Febrile neutropenia; Imipenem; Pharmacodynamics; Pharmacokinetics pharmacodynamics; Population pharmacokinetics

Indexed keywords

IMIPENEM; ANTIINFECTIVE AGENT;

ACINETOBACTER; ADULT; AGED; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; KLEBSIELLA; MALE; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SIMULATION; YOUNG ADULT; ANTIBIOTIC RESISTANCE; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; MONTE CARLO METHOD; SEVERITY OF ILLNESS INDEX;

ACINETOBACTER; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HUMANS; IMIPENEM; IMMUNOCOMPROMISED HOST; INFUSIONS, INTRAVENOUS; KLEBSIELLA; MALE; MIDDLE AGED; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84936867253     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2014.12.003     Document Type: Article

References (29)

1. Rodloff AC, Goldstein E J C, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother. 2006;58:916-929.
2. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broadspectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89-96.
3. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831-847.
4. Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis. 2006;42(Suppl. 2):S72-S81.
5. Lortholary O, Lefort A, Tod M, Chomat AM, Darras-Joly C, Cordonnier C. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis. 2008;8:612-620.
6. Nyhlen A, Ljungberg B, Nilsson-Ehle I. A Swedish Study Group. Pharmacokinetics of meropenem in febrile neutropenic patients. Eur J Clin Microbiol Infect Dis. 1997;16:797-802.
7. Drusano GL, Plaisance KI, Forrest A, Bustamante C, Devlin A, Standiford HC, et al. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1987;31:1420-1422.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
9. Garcia-Capdevila L, Löpez-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B. 1997;692:127-132.
10. Mathews JH. Numerical methods for computer science, engineering and mathematics. London: Prentice-Hall International, Inc.; 1987.
11. Li J, Rhinehart RR. Heuristic random optimization. Comput Chem Eng. 1998;22:427-444.
12. Worakul N, Wongpoowarak W, Boonme P. Optimization in development of acetaminophen syrup formulation. Drug Dev Ind Pharm. 2002;28:345-351.
13. Box G E P, Muller ME. A note on the generation of random normal deviates. Ann Math Statist. 1958;29:610-611.
14. Kimko HC, Duffull SB. Simulation for designing clinical trials: a pharmacokinetic-pharmacodynamic modeling perspective. New York: CRC Press; 2002.
15. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient P-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14:R126.
16. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, et al. Subtherapeutic initial P-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142:30-39.
17. Jaruratanasirikul S, Raungsri N, Punyo J, Sriwiriyajan S. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. J Antimicrob Chemother. 2005;56:1163-1165.
18. Dailly E, Kergueris MF, Pannier M, Jolliet P, Bourin M. Population pharmacokinetics of imipenem in burn patients. Fundam Clin Pharmacol. 2003;17:645-650.
19. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother. 2007;51:3304-3310.
20. Klastersky JA. Use of imipenem as empirical treatment of febrile neutropenia. Int J Antimicrob Agents. 2003;21:393-402.
21. Raad II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer. 2003;98:1039-1047.
22. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal P-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46:2327-2332.
23. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(Suppl. 1):S42-S50.
24. Mouton JW, Touw DJ, Horrevorts AM, Vinks A A T M M. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000;39:185-201.
25. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27:10-22.
26. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding G K M, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32-38.
27. Roberts JA, Kirkpatrick C M J, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2011;66:227-231.
28. Martin JH, Fay MF, Udy A, Robert J, Kirkpatrick C, Ungerer J, et al. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J. 2011;41:537-543.
29. Tanaka A, Suemaru K, Araki H. A new approach for evaluating renal function and its practical application. J Pharmacol Sci. 2007;105:1-5.